This ruling removes a major competitive barrier for EOFlow, which can now commercialize EOPatch 2 without the permanent injunction. For PODD holders, this increases competitive pressure in the insulin patch pump market and eliminates a significant IP victory. Monitor for EOFlow's market entry plans and any potential appeal by Insulet to the Supreme Court (unlikely given Federal Circuit's clear ruling on statute of limitations).
Price Chart
Executive Summary
The Federal Circuit reversed the district court's judgment and permanent injunction against EOFlow, holding that Insulet's trade secret misappropriation claim under the Defend Trade Secrets Act was time-barred because Insulet knew or should have known of the misappropriation before August 3, 2020 (three years before filing suit). The court found undisputed evidence that Insulet had knowledge of EOFlow's access to its trade secrets through a former employee and of striking similarities between the Omnipod and EOPatch 2 by early 2019, triggering the three-year statute of limitations. This ruling vacates the $59.4 million in damages (after reduction) and the permanent injunction that barred EOFlow from commercializing products using Insulet's trade secrets, removing a major overhang on EOFlow's ability to compete in the insulin patch pump market.
Court Ruling Details
Key Facts
- Federal Circuit reversed district court's judgment and permanent injunction against EOFlow in Insulet's trade secret misappropriation case
- Court held Insulet's DTSA claim was time-barred because Insulet knew or should have known of misappropriation before August 3, 2020
- Jury had awarded $170M compensatory and $282M exemplary damages, later reduced to $25.8M compensatory and $33.6M exemplary to avoid double recovery with injunction
- Permanent injunction had barred EOFlow from commercializing products using Insulet's trade secrets worldwide
- Court applied access-plus-similarity framework: knowledge that former employee with trade secret access worked for competitor on similar product starts limitations clock
- Insulet had internal emails from March 2019 noting former employees worked on EOPatch 2, and employees described EOPatch 2 as 'cloned our product' after June 2018 ADA conference
- Dissenting opinion argued majority improperly substituted its fact-finding for the jury's and conflated discovery rule with inquiry-notice standard
Financial Impact
Vacated $59.4M in damages (after reduction) and permanent injunction; Insulet loses trade secret protection and competitive moat against EOFlow's EOPatch 2
Risk Factors
- Insulet may seek Supreme Court review, though certiorari is unlikely on a statute-of-limitations ruling
- EOFlow's EOPatch 2 could gain market share in Europe and South Korea, pressuring Omnipod sales
- Loss of trade secret protection may encourage other competitors to enter the patch pump market
- Insulet's patent claims were dismissed without prejudice but are likely time-barred, leaving no remaining IP claims against EOFlow
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-3ayo3elp-PODD |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $132.30 $148.14 | ▲ +11.97% | ▲ +12.57% | $131.07 (−0.93%) |
Aug 3, 2026 8w ago | Press Release | $169.70 $148.66 | ▲ +12.40% | ▲ +13.64% | $131.07 (+22.76%) |
Jul 30, 2026 9w ago | Press Release | $165.68 $143.41 | ▲ +13.44% | ▲ +17.41% | $131.07 (+20.89%) |
Jul 24, 2026 10w ago | Institutional Cluster | $163.26 $147.92 | ▲ +9.39% | ▲ +13.02% | $131.07 (+19.72%) |
Jul 13, 2026 11w ago | Press Release | $159.12 $144.70 | ▼ −9.06% | ▼ −11.55% | $131.07 (−17.63%) |
Jul 3, 2026 12w ago | Press Release | $159.77 $165.35 | ▼ −3.49% | ▼ −4.06% | $131.07 (+17.96%) |
May 28, 2026 18w ago | Court Ruling | $141.98 $153.82 | ▼ −8.34% | ▼ −11.03% | $131.07 (+7.69%) |
May 6, 2026 21w ago | 8-K | $150.52 $143.30 | ▼ −4.80% | ▼ −7.58% | $131.07 (−12.92%) |
Mar 4, 2026 30w ago | 8-K | $240.55 $204.04 | ▼ −15.18% | ▼ −11.39% | $131.07 (−45.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access